Wells Fargo
ORGO icon

Wells Fargo’s Organogenesis Holdings ORGO Stock Holding History

Wells Fargo’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$141K Buy
57,932
+33,135
+134% +$81K ﹤0.01% 5387
2026
Q1 		$58.8K Sell
24,797
-328,568
-93% -$1.14M ﹤0.01% 5392
2025
Q4 		$1.83M Buy
353,365
+311,409
+742% +$1.51M ﹤0.01% 3518
2025
Q3 		$177K Buy
41,956
+6,657
+19% +$30.9K ﹤0.01% 4999
2025
Q2 		$129K Sell
35,299
-4,919
-12% -$18.3K ﹤0.01% 5042
2025
Q1 		$174K Sell
40,218
-1,253
-3% -$5.06K ﹤0.01% 4802
2024
Q4 		$133K Buy
41,471
+9,464
+30% +$31.8K ﹤0.01% 5040
2024
Q3 		$91.5K Buy
32,007
+1,185
+4% +$3.32K ﹤0.01% 5071
2024
Q2 		$86.3K Buy
30,822
+6,411
+26% +$17.2K ﹤0.01% 5013
2024
Q1 		$69.3K Buy
24,411
+3,141
+15% +$10.7K ﹤0.01% 5104
2023
Q4 		$87K Buy
21,270
+4,262
+25% +$11.9K ﹤0.01% 4992
2023
Q3 		$54.1K Sell
17,008
-10,059
-37% -$32K ﹤0.01% 5136
2023
Q2 		$89.9K Buy
27,067
+12,456
+85% +$36.8K ﹤0.01% 5114
2023
Q1 		$31.1K Buy
14,611
+10,686
+272% +$26.4K ﹤0.01% 5429
2022
Q4 		$10.6K Sell
3,925
-2,196
-36% -$6.41K ﹤0.01% 5531
2022
Q3 		$20K Sell
6,121
-4,835
-44% -$21.8K ﹤0.01% 5401
2022
Q2 		$54K Sell
10,956
-201,056
-95% -$1.24M ﹤0.01% 4986
2022
Q1 		$1.61M Buy
212,012
+4,774
+2% +$37K ﹤0.01% 3493
2021
Q4 		$1.92M Sell
207,238
-284,775
-58% -$3.02M ﹤0.01% 3547
2021
Q3 		$7.01M Buy
492,013
+271,615
+123% +$4.22M ﹤0.01% 2531
2021
Q2 		$3.66M Sell
220,398
-9,874
-4% -$184K ﹤0.01% 3149
2021
Q1 		$4.2M Buy
230,272
+167,072
+264% +$2.26M ﹤0.01% 3008
2020
Q4 		$476K Buy
63,200
+33,230
+111% +$158K ﹤0.01% 4557
2020
Q3 		$115K Buy
29,970
+9,566
+47% +$37.8K ﹤0.01% 5202
2020
Q2 		$78K Buy
20,404
+10,036
+97% +$36.2K ﹤0.01% 5340
2020
Q1 		$33K Sell
10,368
-7,322
-41% -$31.3K ﹤0.01% 5476
2019
Q4 		$85K Buy
17,690
+12,288
+227% +$77.9K ﹤0.01% 5358
2019
Q3 		$36K Buy
5,402
+5,323
+6,738% +$29.6K ﹤0.01% 5654
2019
Q2 		$1K Buy
+79
New +$581 ﹤0.01% 6268

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wells Fargo's ORGO Position: Q2 2026 in Review

Wells Fargo increased its Organogenesis Holdings (ORGO) stake by 134% in Q2 2026, buying an estimated $81K and bringing the position to 57,932 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #5387.

Wells Fargo first reported a position in ORGO in Q2 2019 and has held it in 29 quarters since. The position peaked at $7.01M in Q3 2021. 136 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

  • Wells Fargo held 57,932 shares of Organogenesis Holdings worth $141K as of Q2 2026.
  • Wells Fargo bought 33,135 Organogenesis Holdings shares in Q2 2026, an estimated $81K.
  • Organogenesis Holdings made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5387 holding.
  • Wells Fargo first reported a position in Organogenesis Holdings in Q2 2019 and has held it in 29 quarters since.
  • Wells Fargo's Organogenesis Holdings position peaked at $7.01M in Q3 2021.
  • 136 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.